A prospective observational cohort study involving patients diagnosed with lymphoma treated with CAR-T therapy (axicabtagene ciloleucel, tisagenlecleucel, brexucabtagene autoleucel)
Latest Information Update: 15 Dec 2022
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Brexucabtagene autoleucel (Primary) ; Tisagenlecleucel (Primary)
- Indications Lymphoma
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 15 Dec 2022 New trial record
- 07 Nov 2022 Results presented at the American Heart Association Scientific Sessions 2022